DELAYS & LOSS TO FOLLOW UP: Enrolling patients in a study may involve a third-party evaluation, increasing onboarding time and risking a potential loss to follow up between first visit and enrollment. Additionally, pivotal GO/NO GO decisions can be delayed due to the operational challenges of aggregating data from multiple sites.
A SIGNIFICANT INVESTMENT & RISK: Clinical studies are one of the largest expenses for pharma and life science companies and many risk failure due to suboptimal study design or an inadequate definition of patient subgroups.
With Discovery for Clinical Trials it is possible to:
- Centralize data collection: to increase visibility and monitoring throughout the study development and make real time decisions
- Evaluate in real time enrollment criteria and endpoints: to support patient enrollment with real time data analysis
MONITORING STUDY PROGRESS ANYWHERE AT ANYTIME
SAME DAY PATIENT EVALUATION WORKFLOWS
RetinAI Discovery is a CE-marked medical device according to the Medical Devices Regulation (EU) 2017/745
and the AI models are CE-marked devices according to Medical Devices Directive 93/42/EEC
RetinAI Discovery® is a 510(k) FDA Cleared medical device in US.
RetinAI Discovery® and Retinai® are both trademarks of RetinAI Medical AG.
Discovery and AI Models are CE-Marked medical devices since April 2020 & December 2020 respectively.